Modulation of CCR4 function

Details Modulation of CCR4 function Modulation of CCR4 function

2007-08-28

2007-08-28

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S365000, C514S370000, C514S442000

Reexamination Certificate

active

10654112

ABSTRACT:
Compounds and compositions are provided that bind to the CCR4 chemokine receptor and which are useful for treating diseases associated with CCR4 activity, such as contact hypersensitivity.

REFERENCES:
patent: 2863874 (1958-12-01), Gregory
patent: 3201409 (1965-08-01), Spivack et al.
patent: 3228888 (1966-01-01), Spivack et al.
patent: 3467666 (1969-09-01), Dexter et al.
patent: 3896223 (1975-07-01), Ariyan et al.
patent: 4275210 (1981-06-01), Paget, Jr.
patent: 4826990 (1989-05-01), Musser et al.
patent: 5919776 (1999-07-01), Hagmann et al.
patent: 6207665 (2001-03-01), Bauman et al.
patent: 6426360 (2002-07-01), Weier et al.
patent: 6436967 (2002-08-01), Talley et al.
patent: 6498161 (2002-12-01), Caldwell et al.
patent: 6706767 (2004-03-01), Saxena et al.
patent: 6784195 (2004-08-01), Hale et al.
patent: 2002/0173524 (2002-11-01), Collins et al.
patent: 2003/0018022 (2003-01-01), Collins et al.
patent: 0 310 370 (1989-04-01), None
patent: 1 050 307 (2000-11-01), None
patent: 01 98 1850 (2005-03-01), None
patent: WO 99/04794 (1999-02-01), None
patent: WO 99/38514 (1999-08-01), None
patent: WO 99/38845 (1999-08-01), None
patent: WO 99/42455 (1999-08-01), None
patent: WO 00/41724 (2000-07-01), None
patent: WO 00/42074 (2000-07-01), None
patent: WO 02/30358 (2002-04-01), None
patent: WO 02/34745 (2002-05-01), None
patent: PCT/US02/16395 (2002-10-01), None
Schwarz et al., Recent development in modulating Chemokine networks, Expect Opinion on Therapeutic Patents, 1999, pp. 1471-1489.
Fernandes et al., CA 48:4513g, Apr. 25, 1954.
Das et al., CA 49:11626c, Sep. 10, 1955.
Mahapatra et al., CA 50:962h, Jan. 25, 1956.
Tripathy et al., CA 80:27161, 1974.
Nayak et al., CA 114:23843, 1991.
Pascual, A., 1989, “Preparation of substituted 2-aminooxazole-4-cabonitriles (translated),”Helvetica Chimica Acta72(3):556-569 (with English language abstract).
Mahapatra et al., 1980, “Separation of isometric ureas and oxazoles by thin-layer chromatography,”Journal of Chromatography193:338-339.
Baggiolini et al., 1998, “Chemokines and Leukocyte Traffic,”Nature392:565-568.
Baggiolini et al., 1997, “Blocking Chemokines Receptors Is a Functional Ligand for the CC Chemokine Receptor 4,”J. Biol. Chem. 273:1764-1768.
Imai et al., 1997, “Macrophage-Derived Chemokine Is a Functional Ligand for the CC Chemokine Receptor 4,”J. Biol. Chem. 273:1764-1768.
Imai et al., 1998, “The T-Cell-Directed CC Chemokine TARC is a Highly Specific Biological Ligand for CC Chemokine Receptor 4,”J. Biol. Chem. 272:15036-15042.
Kita et al., 1996, “Chemokines Active on Eosinophils: Potential Roles in Allergic Inflammation,”J. Exp. Med. 183:2421-2426.
Muller et al., 2004, “Chemokines and Chemokine Receptors: Potential Therapeutic Targets in Multiple Sclerosis,”Curr. Drug Targets Inflamm. Allergy3(3):279-290.
National Institute of Health, 2005, Web page (http:www.csr.nih.gov/review/cvsirg.htm) referring to atherosclerosis and Inflammation of the Cardiovascular System [AICS] pp. 1-5.
Sun et al., 2004, “Cytokine-Induced Enhancement of Autoimmune Inflammation in the Brain and Spinal Cord: Implications for Multiple Sclerosis,”Neuropathol. Appl. Neurobiol. 30(4):374-384.

Affiliated with

Also associated with

Rating

Modulation of CCR4 function does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Modulation of CCR4 function, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of CCR4 function will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3872870